Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

ABIOMED's (ABMD) fiscal fourth-quarter performance is likely to reflect growth in Impella product line.

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.

Why Baxter (BAX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Baxter (BAX) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Baxter (BAX) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Baxter (BAX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

by Zacks Equity Research

Baxter (BAX) issues strong guidance for the first quarter of 2020.

Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

Why Earnings Season Could Be Great for Baxter (BAX)

by Zacks Equity Research

Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Growth Prospects Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.

Why Earnings Season Could Be Great for Baxter (BAX)

by Zacks Equity Research

Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

by Zacks Equity Research

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

Baxter's Latest Acquisition to Boost Advanced Surgery Arm

by Zacks Equity Research

Baxter's (BAX) Advanced Surgery arm boasts of a wide spectrum of products.

Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+

by Zacks Equity Research

The latest FDA clearance is likely to boost Baxter's (BAX) Clinical Nutrition segment.

Medical Products' Jan 30 Earnings Roster: TMO, EW & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.

What's in Store for Varian Medical (VAR) in Q1 Earnings?

by Zacks Equity Research

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.

What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?

by Zacks Equity Research

Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.